Acorda CEO Ron Cohen Named BIO Chairman for 2015-2016 Term

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that President and Chief Executive Officer Ron Cohen, M.D, has been elected as the Chair of the Biotechnology Industry Organization (BIO) Board of Directors for the 2015-2016 term. He will also serve as the Chairman of the Health Section Governing Board.

“The biotech industry is among the most innovative in the world, developing life-changing medicines that improve our health, agricultural advances that help us feed an expanding global population, and cleaner, more efficient energy that allows us to fuel our economy while preserving our environment,” said Dr. Cohen. “It is a privilege to help BIO continue to advance our member companies’ collective mission to contribute these extraordinary advances to society.”

The BIO chair is a rotational position. Dr. Cohen will serve in this role through June 2016, and is eligible for re-election for another 1-year term. He previously served as Chair of the Emerging Companies Section Governing Board and Vice Chair of the Health Section Governing Board of BIO.

“Ron Cohen has been an active member of the Board for many years and will bring tremendous passion and a wealth of industry experience to help drive continued growth of BIO and the overall industry,” said Jim Greenwood, BIO President and CEO. “I look forward to working closely with Ron and our newly-constituted Board of Directors in the years to come.”

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS and spinal cord injury.

For more information, please visit the Company’s website at:

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the Civitas transaction and to successfully integrate Civitas' operations into our operations; our ability to successfully market and sell Ampyra in the U.S.; third party payers (including governmental agencies) may not reimburse for the use of Ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra or from our other research and development programs, including CVT-301, Plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market CVT-301, Plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market Fampyra outside of the U.S. and our dependence on our collaboration partner Biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.


Acorda Therapeutics
Jeff Macdonald, 914-326-5232

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.